|
Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2. |
| |
|
Consulting or Advisory Role - ADC Therapeutics; Epizyme; Seagen |
Research Funding - BMS Brazil; Genentech; Kite/Gilead; Merck |
| |
Judit Meszaros Joergensen |
Consulting or Advisory Role - AbbVie; Gilead Sciences; Incyte; Orion; Roche; Sobi |
| |
|
Consulting or Advisory Role - Dr. Reddy's; Genmab; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda |
Research Funding - Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Roche; Takeda |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Janssen; MorphoSys; Novartis; Roche; SOBI; Swixx BioPharma; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Autolus; Bristol-Myers Squibb; Caribou Biosciences; Genmab; Gilead Sciences; Incyte; Janssen; MorphoSys; Novartis; Roche; SOBI; Takeda |
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences; janssen; Roche; SOBI; Takeda |
| |
|
Consulting or Advisory Role - Abbvie; Constellation Pharmaceuticals; Genmab; Gilead Sciences; Regeneron |
Speakers' Bureau - Abbvie; Gilead Sciences; Incyte; Regeneron; Roche; SERVIER |
Research Funding - Morphosys (Inst) |
Travel, Accommodations, Expenses - Abbvie; Incyte |
| |
|
Consulting or Advisory Role - Abbvie; BeiGene; Janssen Oncology; Kite/Gilead |
Travel, Accommodations, Expenses - Kite, a Gilead company |
| |
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics |
Research Funding - Abbvie; AstraZeneca; Loxo/Lilly; Merck; Roche/Genentech; Xencor |
Travel, Accommodations, Expenses - Roche/Genentech |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Kite, a Gilead Company; MSD; Novartis; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Bluebird Bio; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Kite, a Gilead Company; MSD; Mundipharma; Novartis; Sanofi; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Janssen; Kite, a Gilead Company; MSD; Novartis; Sanofi; Takeda |
Research Funding - Takeda |
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Roche; Takeda |
| |
|
Consulting or Advisory Role - Abbvie; BMSi; Eli Lilly Benelux; Novartis; Roche; Takeda |
Research Funding - Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Takeda |
| |
|
Stock and Other Ownership Interests - Genmab |
|
| |
|
Consulting or Advisory Role - Abbvie; Genmab; Incyte; Regeneron; Roche/Genentech; Y-mAbs Therapeutics |
Speakers' Bureau - Abbvie; Lilly |
Research Funding - Takeda (Inst) |
Travel, Accommodations, Expenses - Celgene |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
No Relationships to Disclose |